Psoriasis(Antolrx)

will perform coordinated postmarketing surveillance studies to monitor the effectiveness and safety of system-ic agents, including biologics, in the treatment of psoria-sis. Accordingly, international data can be pooled to reach sufficient power and new drugs can be easily monitored in the future. Established registries try to link to Psonet and new ones are under construction to use the Psocare framework to collect a standardized ‘core set’ of vari-ables. The countries that participate include Italy, France, Israel, Portugal, Spain, Sweden, the Netherlands and the UK. Moreover, the establishment of a multidisciplinary and international group of investigators sharing resourc-es and activities may increase the quality of (pharma-co)epidemiological studies and stimulate the develop-ment of independent pragmatic randomized controlled trials (RCT) that are needed by patients and physicians [4, 5] .I n our opinion, Psocare and Psonet may revolutionize postmarketing and pharmacoepidemiological studies in and outside dermatology. The manufacturers of the pso-riasis drugs should have studied several aims of the these frameworks, but a recent Food and Drug Administration survey showed that only 34% of 2,701 postmarketing commitments were honoured [5, 6] . No such data are available for the European Medicines Agency. Since there is a lack of information about drug behaviour outside the restricted clinical trial population, commercially less in-teresting (hard) outcomes and long-term safety of drugs,

Epidermis-derived cells (NCTC 2544) were cultured and the proteins of the culture medium, as well as of the cells, were fractionated by gel-chromatography. The fractions were analyzed for their papain-inhibitory capacity and for the presence of so-called 43-kDa papain inhibitor. A papain inhibitor was identified with molecular weight and immunological characteristics similar to the original 43-kDa inhibitor that was isolated from psoriatic scales. The result proves that NCTC-2544 cells can produce the so-called psoriasis inhibitor under culture conditions.